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Abstract
Introduction. Chronic renal failure is a significant issue regarding treatment of patients after liver transplantation. One 
of the factors determining the impaired renal function after liver transplantation is a long-term immunosuppressive 
therapy based on calcineurin inhibitors. The objective of the study was to evaluate the dynamics of renal function, 
depending on the use of various calcineurin inhibitors in the long-term postoperative period in liver recipients in real 
clinical practice.
Materials and methods. A retrospective analysis of the renal function in patients operated in the State Public Health 
Budget Institution “Scientific Research Institute – S.V. Ochapovsky Regional Clinic Hospital № 1”, Krasnodar Region, 
was carried out. This article describes dynamics of creatinine level and glomerular filtration rate (GFR) in patients 
before liver transplant, as well as 6 months, 1, 2 and 3 years after surgery. GFR was calculated using the CKD-EPI 
formula (Chronic Kidney Disease Epidemiology Collaboration). Statistical processing of the results was carried out 
using the Statistica 10 software package.
Results and discussion. Before transplantation, the level of creatinine in the blood plasma was 82.9±19.8 mmol/l, 
6 months later a20.4% increase in creatinine was registered (p=0.004), 12, 24 and 36 months later – it increased by 
24.8% (p=0.00001), 24.4% (p=0.0004), and 26.0% (p=0.0005), respectively. Both cyclosporine and tacrolimus caused 
an increase in the level of creatinine. Baseline GFR was 83.4±25.9, the reduction in GFR occurred in comparison with 
the baseline by 14.2% (p=0.0005), 18.8% (p=0.00001), 20.2% (p=0.00003), 22.6% % (p=0.00006) 6, 12, 24 and 36 
months later, respectively. The degree of the decrease in GFR against the background of tacrolimus therapy did not 
differ significantly from that in case of cyclosporine. Verification of chronic kidney disease and the administration of 
statins were recorded in isolated cases.
Conclusions. In liver recipients, the level of creatinine rises and GFR decreases. Reduction of kidney function occurs 
against the background of both inhibitors of calcineurin, in connection with which it is necessary to increase the doctors’ 
alertness for early detection of a decrease in glomerular filtration rate with further verification of chronic kidney disease.
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Introduction
Chronic renal failure is a significant risk factor for the 
deterioration in the prognosis of patients after liver trans-
plantation. With the development of chronic kidney di-
sease (CKD), the risk of death of the liver recipient in-
creases 4.48 times within a year (Gautier et al. 2013). It 
is known that renal insufficiency can be present before 
liver transplantation; it can also develop or worsen during 
transplantation or occur in the early and late postopera-
tive period. One of the reasons determining the impaired 
renal function after liver transplantation is a long-term 
immunosuppressive therapy based on calcineurin inhi-
bitors. Calcineurin inhibitors are considered responsible 
for more than 70% of CKD cases after liver transplan-
tation (Gonwa et al. 2001). In transplantology, this cli-
nic-pharmacological group is represented by tacrolimus 
and cyclosporine. An analysis of foreign literature sho-
wed conflicting data on the severity of nephrotoxicity of 
these drugs in liver recipients (LaMattina et al. 2011, Nae-
sens et al. 2009, Reich et al. 2005, DuBay et al. 2008).
The objective of the study was to evaluate the dynam-
ics of renal function depending on the use of various cal-
cineurin inhibitors in the long-term postoperative period 
in liver recipients, as well as to analyze the compliance 
of the diagnosis and treatment of CKD with the reference 
documents in real clinical practice.
Materials and methods
A retrospective analysis of the patient data (n = 89), who had 
been operated on in the State Public Health Budget Institu-
tion “Scientific Research Institute – S.V. Ochapovsky Regi-
onal Clinic Hospital № 1”, Krasnodar Region, Ministry of 
Public Healthcare was carried out within the framework of 
the register study of liver recipients “Complex Assessment 
of Co-Morbid Pathology after Liver Transplantation (KOM-
PAS-RAN)”. This article analyzes the data of the patients 
before liver transplantation, as well as 6 months, 1, 2 and 3 
years after surgery. The results of the laboratory tests was co-
pied out of the primary medical documentation (outpatient 
medical records [Form No. 025/у-87], in-patient medical re-
cord [medical history, form No. 003/у-80]). The main one is 
glomerular filtration rate (GFR). The level of creatinine and 
GFR were analyzed as the main parameter characterizing the 
functional state of the kidneys in accordance with the current 
“Clinical Practice Guidelines for the Evaluation and Ma-
nagement of Chronic Kidney Disease” (KDIGO 2012). The 
CKD-EPI (Chronic Kidney Disease Epidemiology Collabo-
ration) formula was used as more prognostically valid than 
the Cockcroft-Gold and MDRD formulas (KDIGO 2012).
The statistical processing of the results was carried out 
using the Statistica 10 software package. The data are pre-
sented as M±σ. The results of the study were processed 
by nonparametric methods of statistical analysis using 
the Mann-Whitney test for independent samples and the 
Wilcoxon test for dependent groups. The differences were 
considered significant at a significance level of p<0.05.
Results 
In the local register of liver recipients “Comprehensive 
Evaluation of Co-Morbid Pathology after Liver Trans-
plantation (KOMPAS-RAN)”, 130 patients were inclu-
ded who had undergone orthotopic liver transplantation 
from 2010 to 2017 in the Research Institute Krai Clini-
cal Hospital No. 1. Eighty-nine patients were included 
in the group for the analysis of the dynamics of crea-
tinine and GFR at stages of 6, 12, 24 and 36 months, 
aged 49.6±9.8 years. The gender composition: males – 
52.8%, females – 47.2%.
In most cases, terminal hepatic failure, which caused 
the patient’s need for a donor organ, resulted from virus 
aggression (56.2%), primary biliary cirrhosis (11.2%), 
autoimmune and toxic hepatitis (6.7%), and in 11.2% of 
cases, the etiology of the disease that determines severe 
hepatic failure is not specified. Before transplantation, 
the level of creatinine in the blood plasma was 82.9±19.8 
mmol/l, 6 months afterwasrds an increase in creatinine 
was registered by 20.4% (p=0.004), 12, 24 and 36 months 
after – by 24.8% (p=0.00001), 24.4% (p=0.0004), and 
26.0% (p=0.0005), respectively.
In the analysis, dividing the recipients’ data into the 
groups of those receiving tacrolimus (group 1) and cy-
closporine (group 2) showed that both drugs caused a 
significant increase in plasma creatinine level. Table 1 
shows the results of the analysis of creatinine depend-
ing on the basic immunosuppressive therapy with calci-
neurin inhibitors.
Initially, there were no significant differences in the 
level of creatinine between the groups of the patients who 
had been put on cyclosporine or tacrolimus (Table 1). Six 
moths later, against the background of cyclosporine, cre-
atinine increased by 16.8% (p=0.01), and then by 38.4% 
(p=0.0001), 35.5% (p=0.001) and 51.9% (p=0.001) in a 
year, 24 months and 36 months, respectively. In the tacro-
limus group, creatinine increased 6 months, 1 year, 2 and 
3 years later by 9.2% (p=0.02), 30.7% (p=0.17), 17.8% 
(p=0.02), 23.2% (p=0.009), respectively. The significance 
of the difference between the cyclosporine group and the 
tacrolimus group by the creatinine level was observed at 
all periods, except for 12 months.
In our retrospective study, an assessment of how ad-
equate GFR calculation by physicians in the actual clin-
ical practice is to the recommended formulas was not 
possible in view of the fact that practically no primary 
Table 1. Dynamics of creatinine against the background of cal-
cineurin inhibitors
Parameter Period Tacrolimus Cyclosporine p**
ml/min p* ml/min p*
Creatinine
Before liver 
transplantation 78.8±13.1  84.9±21.7  0.28
6 months 86.1±43.8 0.73 99.2±22.8 0.01 0.03
12 months 103±25.8 0.01 117.5±27.3 0.0002 0.17
24 months 92.8±54.3 0.19 115±30.8 0.001 0.03
36 months 97±24.7 0.02 129±40.1 0.001 0.01
Note: *p – in comparison with the initial value, **p – comparison between cyclo-
sporine and tacrolimus
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Figure 1. Dynamics of glomerular filtration rate when taking cyclosporine and tacrolimus
medical documentation had any records about the glo-
merular filtration rate. For the present study, GFR was 
calculated based on the parameters obtained when copy-
ing the data during the compilation of the retrospective 
part of the KOMPAS-RAN register. The analysis was 
carried out for five time periods – before transplanta-
tion,and 6, 12, 24 and 36 months after liver transplan-
tation. Initially, GFR was 83.4±25.9, 6 months after the 
operation –71.6±21.5, 12 months later – 67.7±21.6, 24 
months and 36 months later – 61.5±20.5, and 64.6±22.6, 
respectively. Thus, GFR decreased in comparison with 
the baseline by 14.2% (p=0.0005), 18.8% (p=0.00001), 
20.2% (p=0.00003), 22.6% % (p=0.00006) 6, 12, 24 and 
36 months later, respectively. In this study, it is impos-
sible to provide the incidence rate of CKD in liver re-
cipients, because according to the up-to-date recommen-
dations, the CKD criteria are a steady decrease in GFR 
for 3 or more months (GFR<60 ml/min/1.73 m2 (GFR 
categories C3a- C5)), as well as a number of other mark-
ers of kidney damage, which cannot be systemized in a 
retrospective study.
The estimation of GFR was carried out in dynamics in 
the subgroups of patients taking various inhibitors of cal-
cineurin. Initially, GFR in these subgroups did not differ 
significantly (83.4±22.2 against tacrolimus, 84.8±22.5 
against cyclosporine (p<0.91). Figure 1 demonstrates the 
unidirectionality of the changes in the indicator regard-
less of the drug taken; the percentages of GFR decrease 
for the periods in the dynamics and the trend line of the 
absolute values of GFR against tacrolimus and cyclospo-
rine are presented.
The intensity of the decrease in GFR on tacrolimus did 
not differ significantly from cyclosporine (Table 2).
At the same time, tacrolimus, unlike cyclosporine, did 
not reduce kidney function 6 months after the operation 
in comparison with the initial value. In the patients taking 
cyclosporine, decreased GFR is proved for all time inter-
vals of the study.
Discussion
In the literature, there are conflicting data on the degree 
of iatrogenic nephrotoxic effect of calcineurin inhibitors. 
For example, in the study by John C. LaMattina and his 
co-authors (LaMattina et al. 2011), calcineurin inhibitors 
were studied in the first post-transplantation year in 724 
patients, which was 99% of all the cases sequentially 
included in the analysis. There were no significant dif-
ferences in the rate of progression of the CKD stage in 
patients treated with cyclosporine in comparison with 
those treated with tacrolimus. Pharmacokinetic analysis 
showed that the average level of drug concentration in the 
bloodstream during the first year, as well as the discon-
tinuation of cyclosporine or tacrolimus, did not predict 
the progression of the CKD stage. It can be assumed that 
the main reason for the continuing debate about the de-
gree of nephrotoxicity of various calcineurin inhibitors is 
the difficulty in comparing the data obtained in different 
laboratories. First, until recently, kidney function was as-
sessed by the level of creatinine, which was reflected in 
the works and conclusions of the years 1980-2013. Sec-
ondly, the authors proposed for analysis any one of the 
periods after transplantation from the first months to sev-
eral years, which, too, could undoubtedly affect the result. 
The authors tried to take into account these nuances and 
make more frequent analytical sections for three years af-
Table 2. Dynamics of GFR against the background of calci-
neurin inhibitors
Parameter Period Tacrolimus Cyclosporine Р**ml/min p* ml/min Р*
Glomerular 
filtration 
rate
Before liver 
transplant 83.4±32.2  84.8±22.5  0.91
6 months 76.9±25.4 0.34 70.8±15.7 0.04 0.24
12 months 66.7±23.8 0.02 65.2±20.3 0.00001 0.89
24 months 68.9±24.2 0.05 64±18.8 0.0004 0.33
36 months 70.1±23.8 0.03 59.7±22.5 0.0006 0.15
Note: *p – in comparison with the initial value, **p – comparison between tacro-
limus and cyclosporine.
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ter the operation, with the data being copied step by step 
at intervals of 6, 12, 24 and 36 months. In addition, as-
sessing the function of the kidneys, the current criteria for 
assessing the function of the kidneys, formulated by the 
experts of the Clinical Practice Guidelines for the Evalu-
ation and Management of Chronic Kidney Disease (KDI-
GO 2012). According to the modern concepts, the main 
parameter characterizing the functional state of the kid-
neys is the glomerular filtration rate, and not the level of 
creatinine. It is the evaluation of GFR that is of consider-
able significance, because in addition to the objective in-
dicator of the functional capacity of the kidneys, it is also 
a predictor of various pathological conditions, includ-
ing cardiovascular complications (Rabelink 2004, Bib-
bins-Domingo et al. 2006, Sarnak 2000, Kobalava 2007, 
Mukhin, Moiseev 2003, Clinical recommendations 2014, 
Smirnov et al. 2005). At the same time, in the world for 
the last 15-20 years, several different formulas have been 
used to calculate GFR, which is the third weighty reason 
why it is difficul to compare the results and conclusions 
from different laboratories. Since 2012 to the present, the 
formula for calculating GFR has been generally accepted 
due to its high prognostic role, not only the level of creat-
inine, but also a number of other indicators. The obtained 
results demonstrated a difference in the manifestation of 
nephrotoxicity of tacrolimus and cyclosporine in three 
post-transplantation periods out of four, if only creatinine 
is used for the analysis of renal function. At the same 
time, evaluation of kidney function by means of GFR did 
not reveal any significant differences in the nephrotox-
ic effect of different calcineurin inhibitors among them-
selves at any period. However, the tendency to better tol-
erability of tacrolimus is present at a 6-month interval, 
where a decline in GFR did not differ significantly from 
the baseline. In addition, absolute values and degrees of 
negative growth also indirectly testify in favour of tac-
rolimus, as a less nephrotoxic drug. Final conclusions 
should be made after prospective well-planned studies. 
Currently, the promise of cyclosporine replacement with 
tacrolimus is possible with manifestations of nephrotox-
icity; however, the protocols for minimizing the doses of 
both calcineurin inhibitors are more intensively studied in 
an attempt to stabilize and even improve kidney function 
and the outcome in recipients (Farkas et al. 2009, Moreno 
et al. 2003, Cantarovich et al. 2003, Creput et al. 2007, 
Koch et al. 2004, Reich et al. 2005, Pageaux et al. 2006, 
Pillebout et al. 2005, Siddharth 2012). It is proposed to re-
place calcineurin inhibitors with less nephrotoxic drugsб 
such as azathioprine, mycophenolic acid and inhibitors of 
the proliferative signal (Sirolimus and Everolimus), or a 
decrease in the dose of calcineurin inhibitors against the 
background of the inclusion of different pharmacologi-
cal subgroups into the immunosuppressant regimen. The 
transplant center solves the issues of reducing the dose 
of calcineurin inhibitors, combining low doses of calci-
neurin with mycophenolate mofetil with or without con-
comitant glucocorticosteroids (GCS), which is safer for 
the kidneys state. The complete withdrawal of calcineurin 
inhibitors and the use of mycophenolate mofetil and GCS 
are associated with a significant risk of graft dysfunction. 
Transition from Sirolimus immunosuppression has a ben-
eficial effect on kidney function if performed 1-2 years 
before the onset of proteinuria, otherwise the kidney 
function in patients with liver transplant will not improve. 
On the other hand, the results were obtained that indicat-
ed the development of nephrotoxicity and a number of 
other side effects when taking immunosuppressants not 
belonging to the group of calcineurin inhibitors (Sim-
one et al. 2009, Campbell et al. 2007, Castroagudin et al. 
2009, Nair et al. 2003, Shenoy et al. 2007, DuBay et al. 
2008). A greater rejection rate is recorded with the exclu-
sion or minimization of calcineurin inhibitors (Burroughs 
et al. 2009, De Simone et al. 2009, Campbell et al. 2007, 
Jensen et al. 2008, Castroagudin et al. 2009, Fairbanks, 
Thuluvath 2004, Bahirwani, Reddy 2009, Shenoy et al. 
2007, DuBay et al. 2008).
Consequently, cyclosporine and tacrolimus remain the 
basic drugs for the prevention of rejection in liver recip-
ients, which makes it urgent to study further in depth the 
risk factors and predictors of the nephrotoxic iatrogenic 
effect and the possibilities for its prevention. From the 
practical point of view, the fact of the deterioration of 
kidney function in comparison with the pre-transplant pe-
riod, proved in the present study within the local register 
of KOMPAS-RAN and practically in all transplant cen-
ters, engaged in the systematization of data on recipients 
in the long-term postoperative period, is important and 
irrefutable. In the recommendations and instructions on 
calcineurin inhibitors , the nephrotoxicity of both repre-
sentatives of the class is mentioned (Siddharth et al. 2012, 
State register of drug products). The experts formulated 
the principles of long-term management of kidney func-
tion after liver transplantation. In particular, a regular 
monitoring of serum creatinine and an assessment of the 
calculated glomerular filtration rate is postulated, at least 
every 6 months, in combination with successive mea-
surements of proteinuria and hematuria, and in patients 
without proteinuria, it is necessary to measure microal-
buminuria. An attempt may be made to minimize doses 
of calcineurin inhibitors early (Naesens et al. 2009, Far-
kas et al. 2009, Siddharth et al. 2012). Collectively with 
transplantologists, a decision should be made about the 
possibility of replacing calcineurin inhibitors with less 
nephrotoxic drugs to prevent donor organ rejection pro-
cesses. Patients who have renal dysfunction should be fol-
lowed up by a nephrologist, since a significant reduction 
in GFR requires the patient to be included in the kidney 
transplant waiting list, which is a method of selecting 
renal replacement therapy, improving the long-term sur-
vival of patients by 44-60% compared with programmed 
hemodialysis (Gautier 2013). Doctors responsible for liv-
er recipients should understand the vital importance of 
timely detection of impaired renal function and timely use 
non-drug and medicinal options to slow the progression 
of chronic kidney disease and to improve the quality and 
life expectancy of liver recipients.
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Conclusions
1. The creatinine level was significantly higher after12- 
and 36-month follow-up in patients taking tacrolimus, 
compared with the baseline, whereas in the presence of 
cyclosporine, an increase in creatinine was recorded in 
all time periods of the study.
2. Tacrolimus and cyclosporine decreased the glomerular 
filtration rate of the kidneys 12, 24 and 36 months later, 
compared to the baseline value before liver transplan-
tation. Unlike, tacrolimus, 6 months after the operati-
on, a decrease in GFR was observed in patients taking 
cyclosporine.
3. The significance of differences in creatinine levels bet-
ween the groups of patients taking cyclosporine and ta-
crolimus was recorded 6, 24 and 36 months later, while 
there were no significant differences in the evaluation 
of kidney function by GFR.
4. Reduction of kidney function occurs against the back-
ground of both inhibitors of calcineurin, in connecti-
on with which it is necessary to increase the doctors’ 
alertness for early detection of a decrease in glome-
rular filtration rate with further verification of chronic 
kidney disease.
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